1:32 PM
 | 
Aug 08, 2018
 |  BC Extra  |  Financial News

Tot raises $102M series B

Cancer company Tot Biopharm Co. Ltd. (Suzhou, China) raised $102 million in a series B round. Participants included China Universal (Cayman) GP Ltd. and other investors as well as existing investors Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.

Tot's pipeline includes TAB008, which is in Phase III testing. TAB008 is a biosimilar of cancer drug Avastin bevacizumab from Roche (SIX:ROG; OTCQX:RHHBY).

Tot also has technology platforms to generate antibody-drug conjugates (ADCs); oncolytic viruses; and liposomal products to treat cancer.

Last year, Tot granted a subsidiary of Lee’s Pharmaceutical Holdings Ltd. (HKSE:0950) exclusive rights in China, including Hong Kong and Macau, to develop and commercialize TAB014, a mAb against VEGF.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD